Weather

102°F11:27 PM

Health

1 read

New Weight Loss Center Opens in West El Paso to Enhance Patient Care

KVIA•Thursday, July 23, 2026 at 6:34 PM•Gabrielle Lopez

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

The Hospitals of Providence has launched a new Weight Loss Center in West El Paso, officially opened with a ribbon-cutting ceremony. This facility, located at 4532 N. Mesa St., is notable for being the only hospital in the area accredited by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. The center aims to provide comprehensive support for weight loss through surgical options, medical treatments, nutritional counseling, and support groups. Dr. Benjamin Clapp will serve as the medical director, focusing on personalized care to help patients achieve their weight loss and health goals. This initiative is significant for the community, offering enhanced access to specialized care.

Key Details: • Weight Loss Center West is located at 4532 N. Mesa St. • The center is accredited by the American College of Surgeons. • Dr. Benjamin Clapp is the medical director of the center. • Services include surgical options, weight loss medications, and nutritional counseling.

community health weight-loss surgery hospitals

People & Organizations

West El PasoHospitals of ProvidenceDr. Benjamin ClappVictoria Gonzalez4532 N. Mesa St.American College of Surgeons

Related Articles

Senate Committee Advances CDC Nominee After Website Update on Vaccines

The Senate Health Committee has postponed a vote on two key health nominations but indicated strong support for Dr. Erica Schwartz as the new CDC director. This backing follows a modification to the CDC's website regarding vaccines and autism, aimed at reassuring the public of vaccine safety. Senator Bill Cassidy emphasized the importance of this change, stating it marks a positive step towards restoring public trust in vaccines. The committee is set to reconvene next week to finalize votes on these nominations, while concerns remain about the nomination of Sean Kaufman to lead the Administration for Strategic Preparedness and Response.

FDA Investigates New Cyclospora Outbreak with 72 Reported Cases

The FDA is currently investigating a cyclospora outbreak that has resulted in at least 72 confirmed cases. This outbreak is particularly concerning as it has not been linked to lettuce, which has been a common source in previous incidents. The investigation aims to identify the source of the contamination to prevent further spread and protect public health. Residents are urged to remain vigilant and report any unusual symptoms to healthcare providers.

Understanding Advanced Prostate Cancer: Insights and Treatments for Patients

Prostate cancer, particularly in its advanced stages, poses significant challenges for patients and their families. While early-stage prostate cancer boasts a five-year survival rate exceeding 99%, this drops to 38% once the cancer metastasizes. Recent advancements in treatment, including the use of combined therapies and improved imaging techniques like PSMA PET scans, have transformed the management of metastatic prostate cancer, allowing patients to live longer and maintain quality of life. Notably, President Biden's ongoing treatment highlights the importance of early intervention and aggressive management in improving outcomes for those diagnosed with this disease. Understanding individual factors, such as Gleason scores and hormone sensitivity, is crucial for tailoring effective treatment plans.

FDA Committee to Discuss Regulation of Popular Peptides This Week

A little-known advisory group from the U.S. Food and Drug Administration (FDA) is set to meet this week to consider easing restrictions on certain injectable peptides, which have gained popularity among wellness influencers and some medical professionals. The meeting, scheduled for Thursday and Friday, will evaluate seven proposed peptides for inclusion in the FDA's '503A Bulks' list, allowing compounding pharmacies to prepare them. However, FDA experts have indicated that there is insufficient evidence regarding the safety and efficacy of these peptides, which are currently unapproved. The outcome of this meeting could significantly impact how these substances are regulated and accessed by the public, particularly for those purchasing them online without medical guidance.